# US 2019/0375743 A1 · Compounds and methods for modulating interleukin-2-inducible t-cell kinase

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0375743 A1
- Document ID: US20190375743A1
- Status: Published application
- Kind: A1
- Application number: 16/346,360
- Filed: 2017-11-03
- Published: 2019-12-12
- Earliest claimed: 2016-11-03
- Assignees: Corvus Pharmaceuticals, Inc.
- Applicants: Corvus Pharmaceuticals, Inc.
- Inventors: Ryan HUDSON; Anne-Marie BEAUSOLEIL
- Web page: https://patentgrep.com/patent/US20190375743A1

## CPC

- C07D 277/54: Nitrogen and either oxygen or sulfur atoms
- C07D 417/12: linked by a chain containing hetero atoms as chain links
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 417/14: containing three or more hetero rings
- C07D 471/08: Bridged systems
- C07D 487/04: Ortho-condensed systems
- C07D 487/08: Bridged systems
- C07D 487/10: Spiro-condensed systems
- C07D 495/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein, inter alia, are methods and compounds for modulating Interleukin-2-inducible T-cell kinase.

## Claims

### Claim 1

A compound having the formula:
wherein,
Ring A is
R1 is independently hydrogen, halogen, —CX13, —CHX12, —CH2X1, —OCX13, —OCH2X1, —OCHX12, —CN, —SOn1R1D, —SOv1NR1AR1B, —NHC(O)NR1AR1B, —N(O)m1, —NR1AR1B C(O)R1C, —C(O)—OR1C, —C(O)NR1AR1B, —OR1D, —NR1ASO2R1D, —NR1AC(O)R1C, —NR1AC(O)OR1C, —NR1AOR1C, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R2 is independently hydrogen, halogen, —CX23, —CHX22, —CH2X2, —OCX23, —OCH2X2, —OCHX22, —CN, —SOn2R2D, —SOv2NR2AR2B, —NHC(O)NR2AR2B, —N(O)m2, —NR2AR2B, —C(O)R2C, —C(O)—OR2C, —C(O)NR2AR2B, —OR2D, —NR2ASO2R2D, —NR2AC(O)R2C, —NR2AC(O)OR2C, —NR2AOR2C, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R3 is independently hydrogen, halogen, —CX33, —CHX32, —CH2X3, —OCX33, —OCH2X3, —OCHX32, —CN, —SOn3R3D, —SOv3NR3AR3B, —NHC(O)NR3AR3B, —N(O)m3, —NR3AR3B, —C(O)R3C, —C(O)—OR3C, —C(O)NR3AR3B, —OR3D, —NR3ASO2R3D, —NR3AC(O)R3C, —NR3AC(O)OR3C, —NR3AOR3C, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R4 is independently hydrogen, halogen, —CX43, —CHX42, —CH2X4, —OCX43, —OCH2X4, —OCHX42, —CN, —SOn4R4D, —SOv4NR4AR4B, —NHC(O)NR4AR4B, —N(O)m4, —NR4AR4B, —C(O)R4C, —C(O)—OR4C, —C(O)NR4AR4B, —OR4D, —NR4ASO2R4D, —NR4AC(O)R4C, —NR4AC(O)OR4C, —NR4AOR4C, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R5 is independently substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
L1 is —O—, —S—, or substituted or unsubstituted C1-C2 alkylene, or substituted or unsubstituted 2 membered heteroalkylene;
L2 is a bond, —NH—, —NHC(O)—;
L3 is a bond, —S(O)2—, —N(R6)—, —O—, —S—, —C(O)—, —C(O)N(R6)—, —N(R6)C(O)—, —N(R6)C(O)NH—, —NHC(O) N(R6)—, —C(O)O—, —OC(O)—, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene;
R6 is independently hydrogen, —CX63, —CHX62, —CH2X6, —CN, —C(O)R6C, —C(O)OR6C, —C(O)NR6AR6B, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
L4 is a bond, —S(O)2—, —N(R7)—, —O—, —S—, —C(O)—, —C(O)N(R7)—, —N(R7)C(O)—, —N(R7)C(O)NH—, —NHC(O) N(R7)—, —C(O)O—, —OC(O)—, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene;
R7 is independently hydrogen, —CX73, —CHX72, —CH2X7, —CN, —C(O)R7C, —C(O)OR7C, —C(O)NR7AR7B, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
E is an electrophilic moiety;
Each R1A, R1B, R1C, R1D, R2A, R2B, R2C, R2D, R3A, R3B, R3C, R3D, R4A, R4B, R4C, R4D, R6A, R6B, R6C, R7A, R7B, and R7C is independently hydrogen, —CX3, —CN, —COOH, —CONH2, —CHX2, —CH2X, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R1A and R1B substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl; R2A and R2B substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl; R3A and R3B substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl; R4A and R4B substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl; R6A and R6B substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl; R7A and R7B substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl;
each X, X1, X2, X3, X4, X6, and X7 is independently —F, —Cl, —Br, or —I;
n1, n2, n3, and n4 are independently an integer from 0 to 4; and
m1, m2, m3, m4, v1, v2, v3, and v4 are independently 1 to 2.

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The compound of claim 1, wherein L1 is —O—, —S—, or substituted or unsubstituted methylene.

### Claim at position 4

4-8. (canceled)

### Claim 9 (depends on 1)

The compound of claim 1, wherein R4 is hydrogen.

### Claim at position 6

10-13. (canceled)

### Claim 14 (depends on 1)

The compound of claim 1, having the formula:

### Claim at position 8

15-17. (canceled)

### Claim 18 (depends on 1)

The compound of claim 1, having the formula:

### Claim at position 10

19-20. (canceled)

### Claim 21 (depends on 1)

The compound of claim 1, wherein R1 is independently hydrogen, halogen, —CX13, —CHX12, —CH2X1, —OCX13, —OCH2X1, —OCHX12, substituted or unsubstituted alkyl, or substituted or unsubstituted heteroalkyl.

### Claim 22

(canceled)

### Claim 23 (depends on 1)

The compound of claim 1, wherein R1 is hydrogen, halogen, —CH3, —CH2CH3, —CX13, —CHX12, —CH2X1, —OCH3, —OCX13, —OCH2X1, —OCHX12, —SCH3, —SCX13, —SCH2X1, or —SCHX12.

### Claim at position 14

24-26. (canceled)

### Claim 27 (depends on 1)

The compound of claim 1, wherein R3 is independently hydrogen, halogen, —CX33, —CHX32, —CH2X3, —OCX33, —OCH2X3, —OCHX32, —CN, substituted or unsubstituted alkyl, or substituted or unsubstituted heteroalkyl.

### Claim 28

(canceled)

### Claim 29 (depends on 1)

The compound of claim 1, wherein R3 is hydrogen, halogen, —CH3, —CH2CH3, —CX33, —CHX32, —CH2X3, —OCH3, —OCX33, —OCH2X3, —OCHX32, —CN, —SCH3, —SCX33, —SCH2X3, or —SCHX32.

### Claim at position 18

30-33. (canceled)

### Claim 34 (depends on 1)

The compound of claim 1, wherein R5 is independently substituted or unsubstituted (C1-C8) alkyl, substituted or unsubstituted 2 to 8 membered heteroalkyl, substituted or unsubstituted (C3-C6) cycloalkyl, substituted or unsubstituted 3 to 6 membered heterocycloalkyl, substituted or unsubstituted phenyl, or substituted or unsubstituted 5 to 6 membered heteroaryl.

### Claim at position 20

35-44. (canceled)

### Claim 45 (depends on 1)

The compound of claim 1, wherein R5 is independently unsubstituted cyclopropyl, unsubstituted cyclobutyl, or unsubstituted cyclopentyl.

### Claim at position 22

46-58. (canceled)

### Claim 59 (depends on 1)

The compound of claim 1, wherein R5 is independently phenyl substituted with halogen, substituted or unsubstituted (C1-C8) alkyl, substituted or unsubstituted 2 to 8 membered heteroalkyl, substituted or unsubstituted (C3-C6) cycloalkyl, substituted or unsubstituted 3 to 6 membered heterocycloalkyl, substituted or unsubstituted phenyl, or substituted or unsubstituted 5 to 6 membered heteroaryl.

### Claim at position 24

60-74. (canceled)

### Claim 75 (depends on 1)

The compound of claim 1, wherein L4 is a bond, —N(R7)—, substituted or unsubstituted monocyclic heterocycloalkylene, substituted or unsubstituted fused ring heterocycloalkylene, substituted or unsubstituted spirocyclic heterocycloalkylene, or substituted or unsubstituted bridged ring heterocycloalkylene; and
R7 is independently hydrogen, —CX73, —CHX72, —CH2X7, or unsubstituted (C1-C4) alkyl.

### Claim at position 26

76-86. (canceled)

### Claim 87 (depends on 1)

The compound of claim 1, wherein L4 is a bond, —NH—,

### Claim at position 28

88-89. (canceled)

### Claim 90 (depends on 1)

The compound of claim 1, wherein E is a covalent cysteine modifier moiety.

### Claim 91 (depends on 1)

The compound of claim 1, wherein
E is
R15 is independently hydrogen, halogen, —CX153, —CHX152, —CH2X15, —CN, —SOn15R15D, —SOv15NR15AR15B, —NHNR15AR15B, —ONR15AR15B, —NHC═(O)NHNR15AR15B, —NHC(O)NR15AR15B, —N(O)m15, —NR15AR15B, —C(O)R15C, —C(O)—OR15C, C(O)NR15AR15B, —OR15D, —NR15ASO2R15D, —NR15AC(O)R15C, —NR15AC(O)OR15C, —NR15AOR15C, —OCX153, —OCHX152, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl;
R16 is independently hydrogen, halogen, —CX163, —CHX162, —CH2X16, —CN, —SOn16R16D, —SOv16NR16AR16B, —NHNR16AR16B, —ONR16AR16B, —NHC═(O)NHNR16AR16B, —NHC(O)NR16AR16B, —N(O)m16, —NR16AR16B, —C(O)R16C, —C(O)—OR16C, —C(O)NR16AR16B, —OR16D, —NR16ASO2R16D, —NR16AC(O)R16C, —NR16AC(O)OR16C, —NR16AOR16C, —OCX163, —OCHX162, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl;
R17 is independently hydrogen, halogen, —CX173, —CHX172, —CH2X17, —CN, —SOn17R17D, —SOv17NR17AR17B, —NHNR17AR17B, —ONR17AR17B, —NHC═(O)NHNR17AR17B, —NHC(O)NR17AR17B, —N(O)m17, —NR17AR17B, —C(O)R17C, —C(O)—OR17C, —C(O)NR17AR17B, —OR17D, —NR17ASO2R17D, —NR17AC(O)R17C, —NR17AC(O)OR17C, —NR17AR17C, —OCX173, —OCHX172, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl;
R18 is independently hydrogen, —CX183, —CHX182, —CH2X18, —C(O)R18C, —C(O)OR18C, —C(O)NR18AR18B, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl;
R15A, R15B, R15C, R15D, R16A, R16B, R16C, R16D, R17A, R17B, R17C, R17D, R18A, R18B, R18C, R18D, are independently hydrogen, —CX3, —CN, —COOH, —CONH2, —CHX2, —CH2X, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R15A and R15B substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl; R16A and R16B substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl; R17A and R17B substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl; R18A and R18B substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl;
each X, X15, X16, X17 and X18 is independently —F, —Cl, —Br, or —I;
n15, n16, n17, v15, v16, and v17, are independently an integer from 0 to 4; and
m15, m16, and m17 are independently 1 or 2.

### Claim at position 31

92-101. (canceled)

### Claim 102 (depends on 1)

The compound of claim 1, wherein E is —C(O)CH═CH2, —C(O)CH═CHCH2N(CH3)2, —C(O)C(═CH2)CH2N(CH3)2, —C(O)C≡CCH3, or —C(O)C(═CH2)CH3.

### Claim 103 (depends on 1)

The compound of claim 1, having the formula:

### Claim at position 34

104-107. (canceled)

### Claim 108 (depends on 1)

A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable excipient.

### Claim at position 36

109-110. (canceled)

### Claim 111 (depends on 1)

A method of treating cancer, said method comprising administering to a subject in need thereof an effective amount of a compound of claim 1.

### Claim at position 38

112-115. (canceled)
